<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Cyclin D1, an important component of cell cycle machinery and a protein with known oncogenic potential, is downregulated in <z:mpath ids='MPATH_458'>normal</z:mpath> mature B lymphocytes </plain></SENT>
<SENT sid="1" pm="."><plain>Its expression detected in a number of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, may be important for <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: In our work, we determined the level of cyclin D1 expression in various B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (i.e., mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) and compared it with <z:mpath ids='MPATH_458'>normal</z:mpath> B cells </plain></SENT>
<SENT sid="3" pm="."><plain>For cyclin D1 level evaluation, the real-time quantitative polymerase chain reaction data was normalized </plain></SENT>
<SENT sid="4" pm="."><plain>We tested five reference genes for stability on our sample set and using the three most stable ones (YWHAZ, ubiquitin c, and HPRT) obtained rather small intra-group variance for cyclin D1 expression in most <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>This allowed their statistically significant ranking according to cyclin D1 expression level </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Median values of normalized cyclin D1 expression determined by real-time quantitative polymerase chain reaction were 1.32 for mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0.02 for B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, 0.009 for diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0.004 for marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0.002 for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> compared with 0.0003 for reactive lymphoid tissue, and 0.00004 for sorted B cells of healthy donors </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Our data demonstrate that mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, a <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with t(11;14)(q13;q32) translocation, has the level of cyclin D1 increased by four orders of magnitude, while other B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> without t(11;14)(q13;q32) translocation still have the level of cyclin D1 significantly elevated above that of <z:mpath ids='MPATH_458'>normal</z:mpath> lymphocytes (2 orders for B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> and an order for other <z:hpo ids='HP_0002665'>lymphomas</z:hpo>) and suggests more than one method of its upregulation in malignant B cells </plain></SENT>
</text></document>